NMI-ChoroidAI, a new application developed by NetraMind Innovations, is now available via Heidelberg App to provide automated, quantitative insights into choroidal health from routine optical coherence tomography (OCT) scans.
NMI-ChoroidAI leverages advanced machine learning to intelligently process Spectralis OCT volume data, automatically segmenting the inner and outer choroidal boundaries and analysing choroidal vasculature. This enables precise 3D segmentation and provides comprehensive measurements of choroidal thickness, volume, and the Choroidal Vascularity Index (CVI). Results are delivered in ETDRS (Early Treatment of Diabetic Retinopathy Study) grid format and detailed tabulated reports, enabling seamless integration into both clinical workflows and research protocols.
With NMI-ChoroidAI, clinicians and researchers gain objective, reproducible, and fully automated analyses in a fraction of the time, enhancing both patient care and scientific discovery
“Accurate assessment of the choroid is essential in understanding and managing retinal diseases such as AMD (age-related macular degeneration, CSCR (central serous chorioretinopathy), and pathological myopia,” said Dr Jay Chhablani, Professor of Ophthalmology at the University of Pittsburgh and Director of the Choroidal Analysis and Research Lab at UPMC Eye Center. “Manual segmentation is often time-consuming and subjective. With NMI-ChoroidAI, clinicians and researchers gain objective, reproducible, and fully automated analyses in a fraction of the time, enhancing both patient care and scientific discovery.”
By providing AI-accelerated segmentation with clinician oversight, intuitive visualisation tools, CVI heat mapping, and streamlined workflow compatibility with HEYEX 2, NetraMind Innovations said NMI-ChoroidAI “transforms a previously tedious process into rapid, clinically valuable insight”.
“With NMI-ChoroidAI on the Heidelberg AppWay platform, ophthalmologists and researchers can now unlock deeper insights into the choroid, helping to improve diagnostic confidence, streamline workflow, and accelerate research into ocular diseases,” said Dr Chhablani.
To be Showcased at AAO
Attendees of the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando (18–20 November, 2025) will have the opportunity to experience a live demonstration of NMI-ChoroidAI at the Heidelberg Engineering booth #3149. Experts from Heidelberg Engineering and NetraMind Innovations will be available to showcase the application’s capabilities and answer questions from clinicians and researchers.
Visit: netramindinnovations.com
*NMI-ChoroidAI by NetraMind Innovations is intended solely as an assistive tool and is currently not CE-marked or cleared by the FDA for clinical use. It is not intended to replace professional medical judgment or to be used in the diagnosis, treatment, or prevention of any disease. Use of these tools in clinical decision-making must be done at the sole discretion and responsibility of the licensed healthcare provider.
NetraMind Innovations’ NMI-ChoroidAI choroidal thickness and CVI analysis report.
NetraMind Innovations’ NMI-ChoroidAI choroidal thickness and CVI analysis report.
Dr Jay Chhablani, Professor of Ophthalmology at the University of Pittsburgh and Director of the Choroidal Analysis and Research Lab at UPMC Eye Centre.
